No Data
Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Short Interest Update
Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Rating) was the target of a significant drop in short interest in the month of July. As of July 15th, there was short interest totalling 285,900 shar
Short Interest in Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Decreases By 41.3%
Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Rating) was the target of a significant decline in short interest in June. As of June 30th, there was short interest totalling 378,600 shares, a dec
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Reshape Lifesciences (NASDAQ:RSLS) shares rose 9.4% to $0.81 during Thursday's after-market session. The market value of their outstanding shares is at $2.8 million. PolarityTE (NASDAQ:PTE) st
Top Premarket Decliners
08:05 AM EDT, 06/09/2022 (MT Newswires) -- Kinetic Holdings (KNTK) shares sank 49% after the company said Wednesday it completed a refinancing plan. India Globalization Capital (IGC) shares were down
Finch Therapeutics to Participate in Upcoming June Investor Conferences
SOMERVILLE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its
Finch Therapeutics Group Files $200 Million Mixed Shelf
04:12 AM EDT, 05/25/2022 (MT Newswires) -- Finch Therapeutics Group (FNCH) on Tuesday filed a shelf registration statement for the potential sale of up to $200 million of its securities from time to t
Finch Therapeutics to Present at the H.C. Wainwright Global Investment Conference
SOMERVILLE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its H
Finch Therapeutics GAAP EPS of -$0.52, revenue of $0.35M
Finch Therapeutics press release (NASDAQ:FNCH): Q1 GAAP EPS of -$0.52.Revenue of $0.35M.Susan Graf appointed board chair and Howard Franklin chief medical officer.Shares +3.59%.
Press Release: Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results -- FDA lifted clinical hold on IND for CP101 -- Enrollment in PRISM4 Phase 3 trial of CP101 in r
Earnings Flash (FNCH) FINCH THERAPEUTICS GROUP Reports Q1 Revenue $354,000
07:03 AM EDT, 05/16/2022 (MT Newswires) --
Loading...